Methods for treating or preventing symptoms of hormonal variations

Abstract

A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT 2A ) and a dopamine type 2 (D 2 ) receptors.

What is claimed is: 
     
         1 . A method for treating or preventing symptoms of hormonal variation, comprising:
 administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT 2A ) receptor and a dopamine type 2 (D 2 ) receptor, and wherein the symotoms of hormonal variation are associated with perimenonause or postmenopause.   
     
     
         2 . The method of  claim 1 , wherein the symptoms of hormonal variation comprises at least one selected from hot flashes, dizziness, nausea, headaches, palpitations, profuse sweating, and night sweats. 
     
     
         3 . The method of  claim 1 , wherein the receptor antagonist is at least one selected from risperidone, 9-hydroxyrisperidone, quetiapine, clozapine, olanzapine, aripiprazole, ziprasidone, and zotepine. 
     
     
         4 . The method of  claim 3 , wherein the effective amount of the receptor antagonist is from 0.1 to 50 mg per day for an adult patient. 
     
     
         5 . The method of  claim 3 , wherein the effective amount of the receptor antagonist is from 0.1 to 20 mg per day for an adult patient. 
     
     
         7 . The method of  claim 3 , wherein the effective amount of the receptor antagonist is from 0.1 to 6 mg per day for an adult patient. 
     
     
         8 . The method of  claim 3 , wherein the effective amount of the receptor antagonist is from 0.1 to 2 mg per day for an adult patient. 
     
     
         9 . The method of  claim 1 , wherein the effective amount of the receptor antagonist is administered by using a pharmaceutically acceptable formulation. 
     
     
         10 . The method of  claim 9 , wherein the pharmaceutically acceptable formulation is an oral formulation, injection, inhalation, or transdermal patch.